Corporate Profile

The ITClamp^®  Hemorrhage Control System by Innovative Trauma Care is designed to address massive hemorrhage – a leading cause of death in traumatic injury – by controlling critical bleeding in seconds.  The clamping device works by sealing the skin closed to create a temporary pool of blood under pressure, which forms a stable clot until the wound can be surgically repaired.  Incorporated in 2010 and based in Edmonton, Canada with a US headquarters in San Antonio, Texas, Innovative Trauma Care is addressing unmet needs in the field of emergency medicine by developing, manufacturing, and commercializing point of injury solutions to treat common causes of preventable death in traumatic injury scenarios.

Leadership

Joseph P. Brennan
PRESIDENT AND CHIEF EXECUTIVE OFFICER

Mr. Brennan is an accomplished leader with over two decades of experience, previously serving in management positions with Genzyme Corporation and Kinetic Concepts, Inc. He also founded sales consulting firm, Redzone Leadership. While at Genzyme, he grew the biosurgical division’s commercial sales from $10 million to over $100 million and supervised multiple diverse teams through his 17-year tenure. In his position with KCI, he achieved year-to-year commercial growth for product lines in the skin substitute and wound care space. He is a graduate of the United States Naval Academy, and served in Operation Desert Storm as a Division Officer on the USS Frederick as well as worked with the Chief of Naval Operations in the Foreign Liaison Office. He has an MBA from the Goizueta Business School at Emory University.

Commander (Ret'd) Dennis F. Filips, MD
FRCSC FOUNDER, VICE-CHAIRMAN, AND CHIEF MEDICAL OFFICER

Dr. Filips, is the principal founder, Vice-Chairman, President, and CMO of iTraumaCare. Dr. Filips, a trauma surgeon, retired from the Canadian Forces (CF) after 20 years of service, completing tours in Afghanistan, Bosnia, and the Golan Heights. He created the Tactical Combat Casualty Care training program, created and chaired the Combat Casualty Working Group for the Canadian Forces, and was a member of the Combat Casualty Care research steering committee for Canada, US, UK, Australia, and New Zealand. Dr. Filips recently carried out consulting research work for Defence Research and Development Canada (DRDC) on combat injury assessment and prevention research. Prior to this he published research findings on hypertonic fluid resuscitation and hemorrhage control with tourniquets. Dr. Filips is currently serving as a course director for Advanced Trauma Life Support (ATLS) courses at the University of Alberta and Tactical Medicine courses for the military and tactical police. He also worked in Haiti with the Red Cross as the chief surgeon at the Notre Dame Hospital in Petit Goave post-earthquake, and is a member of the management team for the Canadian Red Cross rapid deployment field hospital. He has practiced trauma and general surgery at St. Michael’s hospital in Toronto, St. Joseph’s Health Centre in Toronto and at the University of Alberta in Edmonton. In addition to a trauma fellowship at Sunnybrook & Women’s College Health Sciences Centre in Toronto, ON in 2002, he has completed several military trauma-training courses in Los Angeles, CA, Geneva, Switzerland, and London, UK. He completed his general surgery residency at the University of Toronto in 2001 and medical school at Queen’s University (Kingston, ON) in 1991.

Ian Atkinson, PhD.
FOUNDER, CHIEF TECHNOLOGY OFFICER

Dr. Atkinson brings extensive industry experience in technology development, project management, and systems optimization across a broad range of medical, drug development, genomics and biological applications. Prior to joining iTraumaCare, Dr. Atkinson was the chief scientific officer of Biobasix Solutions Inc., a management-consulting firm that developed novel therapeutics for rare disease. His experience includes roles of increasing responsibility in companies including Spiritus Diagnostics, Illumina, Molecular Dynamics/Amersham Pharmacia, and Ignition Sequence. He holds a combined PhD in Genetics and Biological Sciences from the University of Alberta, and conducted his post-doctoral research at the University of California, Berkeley.

Board of Directors

R. Stewart (Randy) Thompson
EXECUTIVE CHAIRMAN OF THE BOARD

Mr. Thompson has been involved with technology start-ups since 1990. As a founder of the first internet service provider in Alberta, Canada, and his building of the first two angel groups in Alberta, Mr. Thompson has put an active stamp on well over 100 start-ups in Western Canada, the United States and the United Kingdom. Currently, Mr. Thompson is the Chief Executive Officer of the VA Angels Forum, which has funded $28.5 million since its inception. With over 70 members across Western Canada, the forum has funded 61 companies since 2003. Mr. Thompson also built Deal Generator, an Angel group of TEC Edmonton and Innovate Calgary, and was a Chapter President for the Keiretsu Forum chapter from 2000 to 2005. His background has led him to speak on Angel investing in China, the United States, and London, United Kingdom as well as be a panelist of both the Angel Capital Association and the National Angel Capital Organization (“NACO”) in Canada. Mr. Thompson has been a NACO board member, an angel investor, advisor, and board member in 13 companies, all in the telco, digital media, digital content, and life sciences.

John Pinsent, FCPA, FCA, ICD.D
Director

Mr. Pinsent is a founding partner of St. Arnaud Pinsent Steman Chartered Professional Accountants (“SPS”). Prior thereto, Mr. Pinsent had a distinguished career with Ernst and Young LLP as an Assurances Senior Manager and as the Director of Technology, Communication and Entertainment assurance services for Northern Alberta. At SPS, Mr. Pinsent specializes in the provision of accounting, audit, tax and business advisory services for owner-managed businesses. Mr. Pinsent has a passion for assisting early stage technology and biotechnology companies and has been an active angel investor and mentor to organizations in this space. During his many years in public practice, he has built a strong network of contacts from various industries and he regularly uses this support network to help his clients and investee companies build value for their enterprises. Mr. Pinsent services on three public company boards, two not-for-profit foundations and several private company boards.

Dr. Ruth Collins-Nakai, MD, MBA, FRCPC, MACC, ICD.D
Director

Dr. Collins-Nakai, an internationally respected pediatric and adult congenital cardiologist, divides her time between clinical practice and health care consulting. She spent over 30 years at the University of Alberta in various roles, including Full Professor and Associate Dean of the Faculty of Medicine & Dentistry, and has served as Commissioner of the Premier’s Commission on Future Health Care for Albertans, President of the Alberta Medical Association, Chair of the Board of Governors of the American College of Cardiology, President of the Canadian Cardiovascular Society, President of the InterAmerican Society of Cardiology, as one of the founding members of the Governing Council of the Canadian Institutes of Health Research and as President of the Canadian Medical Association. In 2001, the International Academy of Cardiovascular Sciences awarded her its Distinguished Achievement Award for promoting cardiovascular education and research throughout the world and in 2005 she was recognized as one of Alberta’s 100 Physicians of the Century. She has also been honored with the YWCA’s Women of Distinction Lois E. Hole’s Lifetime Achievement Award and the Canadian Medical Association’s Medal of Service. She has been named a “Distinguished Citizen” by Grant MacEwan College and in June 2009 was recognized and installed in the Edmonton Hall of Fame for her service to community. In the health and research sphere, she currently serves on the boards of, among others, Genome Alberta and Alberta Health Services.

Commander (Ret’d) Dennis F. Filips, MD, FRCSC
Chief Medical Officer and Director

Dr. Filips in the principal founder, and currently the Chief Medical Officer of the Corporation. Dr. Filips, a trauma surgeon, retired from the Canadian Forces after 20 years of service, completing tours in Afghanistan, Bosnia, and the Golan Heights. He created the Tactical Combat Casualty Care training program, created and chaired the Combat Casualty Working Group of the Canadian Forces, and was a member of the Combat Casualty Care research steering committee for Canada, the United States, the United Kingdom, Australia, and New Zealand. Dr. Filips recently carried out consulting research work for Defence Research and Development Canada on combat injury assessment and prevention research.

Dr. Filips is currently serving as a course director for Advanced Trauma Life Support courses at the University of Alberta and Tactical Medicine courses for the military and tactical police. He also worked in Haiti with Red Cross as the chief surgeon at the Notre Dame Hospital in Petit Goave post-earthquake, and is a member of the management team for the Canadian Red Cross rapid deployment field hospital.  He has practiced trauma and general surgery at St. Michael’s hospital in Toronto, St. Joseph’s Health Centre in Toronto and the University of Alberta in Edmonton. In addition to a trauma fellowship at Sunnybrook & Women’s College Health Sciences in Toronto, Ontario in 2002, he has completed several military trauma-training courses in Los Angeles, California, Geneva, Switzerland and London, United Kingdom. He completed his general surgery residency at the University of Toronto in 2001 and medical school at Queen’s University in 1991.

Ian Atkinson, Ph.D.,
Chief Technology Officer and Director

Dr. Atkinson is a founder and Chief Technology Officer of the Corporation. He brings extensive industry experience in technology development, project management, and systems optimization across a broad range of medical, drug development, genomics and biological applications. Prior to joining the Corporation, Dr. Atkinson was the Chief Scientific Officer of Biobasix Solutions Inc., a management-consulting firm that developed novel therapeutics for rare disease. His experience includes roles of increasing responsibility in companies including Spiritus Diagnostics, Illumina, Molecular Dynamics/Amersham Pharmacia, and Ignition Sequence. He holds a combined PhD in Genetics and Biological Sciences from the University of Alberta, and conducts his post-doctoral research at the University of California, Berkeley.

Paul Castella, Ph.D.
Director

Dr. Paul Castella has experience in the evaluation, financing, licensing, formation and operation of biotechnology and medical technology companies. Paul specializes in financing and licensing strategies for technology start-ups, and in 2009, Paul cofounded Targeted Technology Fund I, LP. Previously, Paul co-founded and served as the President and CFO of CardioSpectra, which was formed in late 2005 and acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007 for $63M in upfront payments and milestones. Paul is a board member for Xenotope Diagnostics, BioDtech, BiO2 Medical, ViroXis Corporation, Santalis Pharmaceuticals, StemBioSys and Soluble Therapeutics, and an advisory board member of the Chromosome 18 Registry, the Center for Technology Entrepreneurship and Innovation at UTSA (CITE), and the University of Texas San Antonio School of Business. Paul received his PhD in Cell Biology and Genetics from Cornell University Medical College in Manhattan, where he was the first-ever recipient of the Weill Graduate School Award of Excellence. He received his MBA from the University of Texas at San Antonio. Paul holds numerous issued and pending patents, and in 2008 was inducted into San Antonio’s “SATAI Technology Hall of Fame.

Joseph P. Brennan
President and Chief Executive Officer

Mr. Brennan is the President and Chief Executive Officer of the Corporation. He is an accomplished leader with over two decades of experience, previously serving in management positions with Genzyme Corporation and Kinetic Concepts, Inc. (“KCI”). He also founded sales consulting firm, Redzone Leadership.  While at Genzyme, he grew the biosurgical division’s commercial sales from $10 million to over $100 million and supervised multiple diverse teams through his 17-year tenure. In his position with KCI, he achieved year-to-year commercial growth for product lines in the skin substitute and wound care space. He is a graduate of the United States Naval Academy, and served in Operation Desert Storm as a Division Officer on the USS Frederick as well as worked with the Chief of Naval Operations in the Foreign Liaison Office.  He has an MBA from the Goizueta Business School at Emory University.